Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 530 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations November 13, 2019 ESMO Congress 2022, 9-13 September August 22, 2022 FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma April 29, 2021 How Some Brain Tumors Hijack the Mind to Grow June 21, 2023 Load more HOT NEWS New targeted treatment for early breast cancer could reduce risk of... Immunotherapy approved for some people with advanced melanoma in England A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and... Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than...
